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Abstract
Background: The presence of the TMPRSS2-ERG fusion gene in prostate tumors has recently
been associated with an aggressive phenotype, as well as recurrence and death from prostate
cancer. These associations suggest the hypothesis that the gene fusion may be used as a prognostic
indicator for prostate cancer.
Methods: In this study, fluorescent in situ hybridization (FISH) assays were used to assess
TMPRSS2-ERG fusion status in a group of 214 prostate cancer cases from two population-based
studies. The FISH assays were designed to detect both fusion type (deletion vs. translocation) and
the number of fusion copies (single vs. multiple). Genotyping of four ERG and one TMPRSS2 SNPs
using germline DNA was also performed in a sample of the cases (n = 127).
Results: Of the 214 tumors scored for the TMPRSS2-ERG fusion, 64.5% were negative and 35.5%
were positive for the fusion. Cases with the TMPRSS2-ERG fusion did not exhibit reduced prostate
cancer survival (HR = 0.92, 95% CI = 0.22–3.93), nor was there a significant difference in cause-
specific survival when stratifying by translocation or deletion (HR = 0.84, 95% CI = 0.23–3.12) or
by the number of retained fusion copies (HR = 1.22, 95% CI = 0.45–3.34). However, evidence for
reduced prostate cancer-specific survival was apparent in those cases whose tumor had multiple
copies of the fusion. The variant T allele of the TMPRSS2 SNP, rs12329760, was positively
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gene fusion (p = 0.03).
Conclusion: If replicated, the results presented here may provide insight into the mechanism by
which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for
determining the subset of men who will go on to develop metastatic prostate cancer.
Background
There is considerable interest in the relationship between
the TMPRSS2-ERG gene fusion and prostate cancer risk.
Two studies, published in 2005, identified ERG as the
most over-expressed proto-oncogene in prostate cancer
tumors [1] and demonstrated that this over-expression is
often caused by a fusion of the promoter region of the
TMPRSS2 gene to a variety of genes [2]. Tomlins and col-
leagues (2005) identified recurrent gene fusions of
TMPRSS2 to two ETS transcription factors, ERG and ETV1,
and found evidence to suggest that these fusions may
occur in the majority of prostate cancer cases [2].
Several subsequent studies have suggested that the
TMPRSS2-ERG fusion protein is not only present in late
stage prostate cancer [2-8] but in benign prostatic hyper-
plasia (BPH) [9], high-grade prostate intra-epithelial neo-
plasia (HGPIN) [3,10] and even in non-malignant tissue
adjacent to prostate cancer foci [9,10]. During the course
of these investigations, it has been discovered that there
are a large number of unique TMPRSS2-ERG fusion tran-
scripts, with up to 19 identified to date [7,9,11]. Interest-
ingly, the majority of these transcripts, including the most
commonly found T1/E4 variant, encode either truncated
or null fusion proteins [7,9,11]. While some of the diver-
sity may be due to alternative splicing, it has become
apparent that other recombination mechanisms may also
contribute to the distinct fusion transcripts. Several stud-
ies using FISH have demonstrated that the TMPRSS2-ERG
fusion can result from both translocations and interstitial
deletions between TMPRSS2 and ERG [5,11-14], with
deletion being suggested as a common mechanism for
fusion formation [11,15,16]. In addition, it has been
demonstrated that while individual tumor foci are homo-
geneous for fusion status, within a single case heterogene-
ity between tumor foci also exists [8,9,17].
Several studies have focused on elucidating the role of the
TMPRSS2-ERG gene fusion in prostate cancer. The gene
fusion has been found to be associated with moderate to
poorly differentiated prostate tumors [18], disease recur-
rence [4], progression and prostate cancer-specific death
[15,19], and conversely, longer progression-free survival
[20,21]. When investigating the many TMPRSS2-ERG iso-
forms, Wang and colleagues (2006) found expression of
isoforms in which the native TMPRSS2 or ERG ATG start
codon is in-frame are associated with aggressive disease
and poor outcomes compared to non-native internal
ATGs [7]. In addition, when investigating the type of
TMPRSS2-ERG fusion, formation through deletion, rather
than translocation, was associated with risk factors for dis-
ease progression [5] and significantly worse cause-specific
and overall survival [15]. The latter study also found that
deletion accompanied by duplication of the TMPRSS2-
ERG fusion exhibited extremely poor cause-specific sur-
vival, providing prognostic information additional to that
provided by Gleason score and PSA levels [15]. In fact,
multiple studies have found no association between
TMPRSS2-ERG fusion and Gleason score
[8,11,14,17,20,22,23] or pathologic stage
[8,11,14,20,23]. Further insight was provided by Her-
mans and colleagues (2006), who suggest that TMPRSS2-
ERG may play a key role in androgen-dependent prostate
cancer. While both androgen-dependent and androgen-
independent tumors contain the fusion gene, only the
former show overexpression of ERG and the fusion tran-
scripts [12].
The main objective of the current study was to determine
whether the TMPRSS2-ERG gene fusion was associated
with prostate cancer-specific mortality in tumors from
372 patients ascertained from a population-based cancer
registry and with long-term surveillance after cancer diag-
nosis. The second objective of this study was to investigate
whether germline single nucleotide polymorphisms
(SNPs) present in the ERG and TMPRSS2 genes are associ-
ated with TMPRSS2-ERG fusion status.
Methods
Study Subjects and Tumor Tissue
Tumor tissue blocks were collected from either radical
prostatectomy specimens (n = 355, 95.4%) or TURP (n =
17, 4.6%), and were used to create tissue microarrays
(TMAs). Patients from King County, Washington, were
diagnosed with histologically confirmed prostate cancer
from January 1, 1993 through December 31, 1996, and
were identified via the Seattle-Puget Sound SEER Cancer
Registry. The SEER registry provided information on
Gleason score, stage of cancer, diagnostic PSA level and
primary therapy. Vital status and underlying cause of
death were also ascertained through the SEER cancer reg-
istry and collection of death certificates; November 15,
2007 was the most recent update of patient outcomes. The
patients originate from two different studies. The firstPage 2 of 10
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64 years, is part of a larger population-based case-control
study consisting of 753 cases (subsequently referred to as
Study I). The remaining 102 men, diagnosed between the
ages of 60 and 88 years, are a subset of 372 patients who
participated in a quality of life study (subsequently
referred to as Study II). All patients signed informed con-
sent for participation and the studies were approved by
the Fred Hutchinson Cancer Research Center Institutional
Review Board. Both of these studies are described in detail
elsewhere [24-26].
Tissue Microarrays and FISH Assay
A total of 372 paraffin embedded tumor blocks was used
to build the TMAs. Of these specimens, eight were selected
as blind duplicates for quality control purposes resulting
in 380 cores being represented on the TMAs. H&E stained
slides were reviewed for each case and areas containing
tumor were marked on both the slides and corresponding
paraffin blocks for TMA construction. Three cores per case,
taken from a single tumor focus, were represented on the
TMAs. The TMAs were constructed using a manual arrayer
(Beecher Instruments) with tissue core diameters of 0.6
mm. Each section was baked overnight at 60°C, then
deparaffinized in xylene and rinsed with 100% ethanol.
Sections were pretreated as described previously [27].
FISH analysis was performed using the following BACs
(BACPAC Resources Centre, Children's Hospital Oakland
Research Institute, Oakland, CA): RP11-95I21 (5' ERG),
RP11-476D17 (3' ERG) and RP11-35C4 (telomeric to
TMPRSS2; Figure 1). BACs RP11-95I21 and RP11-35C4
were directly labeled by nick translation with Spectrum
Green and Spectrum Orange respectively (Vysis, Downer's
Grove, IL). BAC RP11-476D17 was indirectly labeled
using a modified protocol with Streptavidin-Cy5 (Meta-
Systems, Belmont, MA) using the BioPrime DNA labeling
Relative locations of BAC probes on chr21q22 for FISH assaysFigure 1
Relative locations of BAC probes on chr21q22 for FISH assays. A) Normal chromosome. B) TMPRSS2-ERG fusion by 
translocation. C) TMPRSS2-ERG fusion by deletion.Page 3 of 10
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formed using Vysis or MetaSystems reagents according to
manufacturers' protocols. FISH signals were visualized on
a Zeiss Axioplan epifluorescent microscope and captured
using MetaSystems ISIS FISH imaging software (MetaSys-
tems, Belmont, MA). Evaluation of the FISH results from
each case was independently performed by 2 operators
(KJ, MM). A total of 50 epithelial nuclei per case was eval-
uated across the three cores and to be classed positive for
the TMPRSS2-ERG fusion, evidence needed to be present
in at least 20% of the cells. Each individual was scored as
follows (Figure 1 and 2): normal (three combined signals
indicating no rearranged TMPRSS2 or ERG loci); positive
for the fusion with translocation (combined red/blue sig-
nals with separate green 5' ERG signal); positive for the
fusion with deletion (combined red/blue signals with the
absence of the green 5' ERG signal); or not scored
(absence of a FISH signal, low cellularity or core(s) dis-
lodged from array). It was also noted whether multiple
copies of the particular TMPRSS2-ERG fusion were
present in a single nucleus.
ERG and TMPRSS2 SNP Genotyping
Four SNPs within the ERG gene and one SNP within the
TMPRSS2 gene were selected for genotyping using germ-
line DNA isolated from peripheral blood samples using
standard methods. The ERG SNPs were chosen based on
results obtained from the CGEMS study (p ≤ 0.05) [28]
and included rs1571704, rs1892570, rs2068967 and
rs2836370. The TMPRSS2 SNP, rs12329760
(Met160Val), was chosen as it was previously found to be
associated with prostate cancer in men with a first-degree
family history of the disease [29]. Genotyping data were
only available for a subgroup (N = 126) of Study I partic-
ipants.
The Applied Biosystems (ABI) SNPlex™ Genotyping Sys-
tem was used for genotyping and proprietary GeneMap-
per® software was used for allele calling [30].
Discrimination of the specific SNP allele was carried out
on the ABI 3730xl DNA Analyzer and is based on the pres-
ence of a unique sequence assigned to the original allele-
specific oligonucleotide. In 140 blind duplicate samples
distributed across all genotyping batches, there was 100%
agreement between the blinded samples for each of the
five SNPs.
Statistical Analysis
Demographic and clinical characteristics were compared
between prostate cancer cases whose tumor could not be
scored and those who were positive or negative for the
TMPRSS2-ERG fusion. The primary endpoint for the sur-
vival analyses was time to death from prostate cancer. Sur-
vival time, i.e., time elapsed from diagnosis until death,
was the time-dependent variable used. In each case, a
death certificate was obtained to confirm the event. Living
cases were censored as of November 15th, 2007. The asso-
ciation between prostate cancer specific-survival and
TMPRSS2-ERG fusion status was evaluated using Kaplan-
Meier estimator functions and Cox's proportional hazard
models [31] to estimate hazard ratios (HR) and 95% con-
fidence intervals (CI). First, survival analysis models were
examined adjusting only for age at diagnosis, and then
models were adjusted for Gleason score. Associations
between genotyping data and TMPRSS2-ERG fusion status
were examined using Fisher's exact test. All reported p-val-
FISH detection of TMPRSS2 and ERG gene statusigure 2
FISH detection of TMPRSS2 and ERG gene status. A) No TMPRSS2-ERG fusion. B) Positive for the TMPRSS2-ERG 
fusion with translocation – arrows indicate the separate green 5' ERG signal. C) Positive for the TMPRSS2-ERG fusion with 
deletion – arrows indicate the combined blue/red TMPRSS2 and 3' ERG signal and the absence of the green 5' ERG signal. FISH 
signals in these pseudo-colored images are red (telomeric to TMPRSS2; RP11-35C4), green (5' ERG; RP11-95I21) and blue (3' 
ERG; RP11-476D17). Note that in non-rearranged chromosomes the proximity of the green and blue signals can result in an 
aqua-colored signal.Page 4 of 10
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analyses.
Results
Demographic and Clinical Results
Demographic and clinical characteristics of patients are
provided in Table 1. Of the 372 unique prostate tumors,
214 (57.4%) were scored for the TMPRSS2-ERG fusion,
one tumor (0.3%) was equivocal and 157 (42.4%)
tumors were not scored due to technical issues (core drop-
off or failed hybridization). There were no significant dif-
ferences in age at diagnosis or clinical characteristics
between those cases not scored and those scored for the
TMPRSS2-ERG fusion. Of the 8 replicates present on the
TMAs, equivalent results were obtained in the 4 samples
with results from both replicates. After removing one of
each replicate pair, 138 (64.5%) tumors scored negative
and 76 (35.5%) tumors scored positive for the TMPRSS2-
ERG fusion (Table 1). Of the tumors scored positive for
the fusion transcript, 38 (50%) were fusion by transloca-
tion and 38 (50%) were fusion by deletion of the inter-
vening chromosomal region (Table 1). There were no
differences in the distributions of demographic or clinical
characteristics between cases positive for the TMPRSS2-
ERG fusion and those negative for the fusion. However, a
higher proportion of prostate cancer-specific deaths was
observed in cases whose tumor was positive for the
TMPRSS2-ERG fusion in comparison to those without,
7.9% vs. 4.4% respectively (p = 0.35).
Survival Analysis
Prostate cancer-specific survival was evaluated for the 214
cases scored for the TMPRSS2-ERG fusion and these
results are summarized in Kaplan-Meier plots (Figure 3).
The mean survival time for all cases after diagnosis was
11.6 years (range 1 to 14 years). The mean survival time
did not differ significantly between cases positive or nega-
tive for the TMPRSS2-ERG fusion, between cases with dif-
ferent fusion types (translocation vs. deletion) or between
cases with different fusion copy numbers (single vs. mul-
tiple; Table 2). Multivariate Cox analysis, adjusted for age,
demonstrated that a reduced, but not significant, cause-
specific survival was observed in patients with fusion pos-
itive tumors, when compared to patients whose samples
retain normal TMPRSS2 and ERG FISH patterns (HR =
2.4, 95% CI = 0.74–7.57). However, after adjusting for
Table 1: Demographic and clinical characteristics of prostate cancer patients by tumor TMPRSS2-ERG gene fusion status.
TMPRSS2-ERG Gene Fusion Status
Characteristics Not Scored1 Positive Negative
n = 158 n = 76 n = 138
Age at diagnosis
Mean (SD) 61.2 (7.4) 59.3 (6.3) 59.9 (7.2)
Range 40 – 86 45 – 88 45 – 86
Gleason score (%)
2 - 7 (3+4) 138 (87.3) 63 (82.9) 115 (83.3)
7 (4+3) - 10 17 (10.8) 12 (15.8) 19 (13.8)
Missing 3 (1.9) 1 (1.3) 4 (2.9)
Stage (%)
Local 121 (76.6) 57 (75) 106 (76.8)
Regional 37 (23.4) 18 (23.7) 29 (21.0)
Distant 0 (0) 1 (1.3) 3 (2.2)
PSA value at diagnosis (ng/ml) (%)
0 – 9.9 92 (58.2) 52 (68.4) 91 (65.9)
≥ 10.0 41 (26.0) 16 (21.1) 29 (21.0)
Missing 25 (15.8) 8 (10.5) 18 (13.1)
Vital status (%)
Alive 129 (81.7) 65 (85.5) 119 (86.2)
Deceased
Prostate cancer-specific death 4 (2.5) 6 (7.9) 6 (4.4)
Other cause of death 25 (15.8) 5 (6.6) 12 (8.7)
Missing 0 (0) 0 (0) 1 (0.7)
Fusion Type
Translocation - 38 (50) -
Deletion - 38 (50) -
Fusion Number
Single - 65 (85.5) -
Multiple - 11 (14.5) -
Survival Time (years) (SD) 11.5 (2.6) 12.0 (2.6) 11.4 (3.1)
1Includes one equivocal case.Page 5 of 10
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ated (HR = 1.2, 95% CI = 0.34–4.02; Table 2). Similarly,
no significant differences in cause-specific survival were
observed when stratifying the fusion samples by translo-
cation or deletion (HR = 1.18, 95% CI = 0.52–2.71; Table
2), or by the number of retained copies (HR = 1.46, 95%
CI = 0.54–3.88; Table 2). However, even after adjusting
for age and clinicopathological factors, there was some
evidence that samples with multiple copies of the fusion
conferred worse survival than those with no fusion or sin-
gle copies of the gene fusion.
ERG and TMPRSS2 Genotyping Results
Examination of the associations between ERG and
TMPRSS2 genotypes and the presence of the fusion gene,
fusion type and fusion copy number are presented in
Table 3. Polymorphisms present in the ERG gene were not
related to the presence of the gene fusion, fusion type
(translocation vs. deletion) or fusion copy number (single
vs. multiple; Table 3). Presence of the variant allele of the
TMPRSS2 SNP, rs12329760, was not associated with the
presence of the TMPRSS2-ERG fusion (Fisher's Exact test;
p = 0.13; Table 3), but men with a variant T allele were
more likely to have fusion by translocation (χ2 test; p =
0.05; Table 3) and to have multiple copies of the gene
fusion (χ2 test; p = 0.03; Table 3).
Discussion
In the 214 prostate cancer patients scored for fusion sta-
tus, we found that the presence of the TMPRSS2-ERG
fusion was not associated with prostate cancer-specific
mortality. Similarly, no statistically significant association
was found between prostate cancer-specific mortality and
fusion type (translocation vs. deletion) or number (single
vs. multiple). However, there was a suggestion of higher
prostate cancer-specific mortality in those patients with
multiple fusion products. In addition, we found the
rs12329760 SNP in TMPRSS2 to be significantly associ-
ated with fusion by translocation and with multiple cop-
ies of the fusion protein.
Currently, only two previous studies have investigated the
relationship between fusion status and prostate cancer-
specific mortality [15,19]. Consistent with the results pre-
sented here, Demichelis and colleagues (2007) observed
no significant association between TMPRSS2-ERG gene
Table 2: Patient mean survival time and Cox regression analysis of TMPRSS2-ERG fusion status
Fusion Status Survival Time (SD)1 HR (95% CI)2 p-value HR (95% CI)3 p-value
Negative 11.4 (3.1)
Positive 12.0 (2.6) 2.4 (0.7 – 7.6) 0.3 1.2 (0.3 – 4.0) 0.8
Negative 11.4 (3.1)
Translocation 12.0 (2.9)
Deletion 12.0 (2.2) 1.5 (0.7 – 2.9) 0.3 1.2 (0.5 – 2.7) 0.5
Negative 11.4 (3.1)
Single 12.1 (2.3)
Multiple 11.5 (4.1) 1.9 (0.9 – 4.1) 0.09 1.5 (0.6 – 3.9) 0.9
1Time elapsed from diagnosis until death; 2Age adjusted; 3Age & Gleason score adjusted.
Kaplan-Meier survival estimatesFigure 3
Kaplan-Meier survival estimates. A) Patients with and without TMPRSS2-ERG gene fusion. B) Patients with no TMPRSS2-
ERG fusion, patients with fusion by translocation and patients with fusion by deletion. C) Patients with no TMPRSS2-ERG 
fusion, patients with a single fusion and patients with multiple fusions.Page 6 of 10
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adjusted for Gleason score and age (p = 0.2) [19]. By com-
parison, Attard and colleagues (2007) did not present
results for overall fusion status however, they did show
that fusions caused by deletion had significantly worse
disease-specific mortality and this association was largely
driven by tumors with two or more copies of the fusion
product [15]. While we also observed suggestive evidence
for higher prostate cancer-specific mortality in patients
with multiple fusion products, we did not observe an
association with fusion type (translocation or deletion).
This could be due to a number of differences between our
study and Attard and colleagues' [15]. Although the fol-
low-up time of this study was greater than that of Attard et
al. (median 12.3 years vs. 7.5 years), there were fewer
prostate cancer-specific deaths during this time that could
be attributed to the younger median age of diagnosis (60
years) and fewer cases with a Gleason score of > 7. As
Gleason score is a strong, independent predictor of
adverse outcomes and we have a relatively young group of
patients, it may require a longer follow-up time to observe
a potential association between prostate cancer-specific
death and TMPRSS2-ERG fusion type (translocation/dele-
tion) or number (single/multiple).
While not statistically significant, when unadjusted for
Gleason score, we found that there was some evidence for
higher prostate cancer-specific mortality in patients with
fusions caused by translocation but not deletion. Attard
and colleagues (2007) suggest that the sequence interven-
ing the TMPRSS2 and ERG genes may contain tumor-sup-
pressor genes which when lost, increase disease
Table 3: Association between ERG and TMPRSS2 SNP genotypes and TMPRSS2-ERG fusion status
Fusion Status
Gene SNP Genotype Negative Positive P value
ERG rs1571704 GG 66 (84.6) 43 (89.6)
GT/TT 12 (15.4) 5 (10.4) 0.59
rs1892570 CC 64 (81.0) 44 (91.7)
CT/TT 15 (19.0) 4 (8.3) 0.13
rs2068967 GG 24 (30.4) 15 (31.3)
GA/AA 55 (69.6) 33 (68.7) 0.10
rs2836370 TT 18 (22.5) 12 (25.5)
TC/CC 62 (77.5) 35 (74.5) 0.83
TMPRSS2 rs12329760 CC 53 (68.0) 26 (53.1)
CT/TT 25 (32.0) 23 (46.9) 0.13
Negative Translocation Deletion
ERG rs1571704 GG 66 (84.6) 18 (85.7) 25 (92.6)
GT/TT 12 (15.4) 3 (14.3) 2 (7.4) 0.66
rs1892570 CC 64 (81.0) 19 (90.5) 25 (92.6)
CT/TT 15 (19.0) 2 (9.5) 2 (7.4) 0.33
rs2068967 GG 24 (30.4) 9 (42.8) 6 (22.2)
GA/AA 55 (69.6) 12 (57.2) 21 (77.8) 0.31
rs2836370 TT 18 (22.5) 5 (23.8) 7 (26.9)
TC/CC 62 (77.5) 16 (76.2) 19 (73.1) 0.91
TMPRSS2 rs12329760 CC 53 (68.0) 8 (38.1) 18 (64.3)
CT/TT 25 (32.0) 13 (61.9) 10 (35.7) 0.05
Negative Single Multiple
ERG rs1571704 GG 66 (84.6) 40 (93.0) 3 (60.0)
GT/TT 12 (15.4) 3 (7.0) 2 (40.0) 0.09
rs1892570 CC 64 (81.0) 40 (93.0) 4 (80.0)
CT/TT 15 (19.0) 3 (7.0) 1 (20.0) 0.15
rs2068967 GG 24 (30.4) 12 (27.9) 3 (60.0)
GA/AA 55 (69.6) 31 (72.1) 2 (40.0) 0.36
rs2836370 TT 18 (22.5) 11 (26.2) 1 (20.0)
TC/CC 62 (77.5) 31 (73.8) 4 (80.0) 0.86
TMPRSS2 rs12329760 CC 53 (68.0) 25 (58.1) 1 (16.7)
CT/TT 25 (32.0) 18 (41.9) 5 (83.3) 0.03Page 7 of 10
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(2006) identified significantly down-regulated genes
located in the area of the common deletion site, of which
at least one, HMGN1, has been associated with tumor
growth in mice and primary mouse embryonic fibroblast
cell lines [32]. While deletion of this intervening region
could explain the poorer outcome, it is not implausible
that translocation could also disrupt the expression of
these intervening genes in such a way to cause adverse out-
comes. Clearly more work needs to be done, first to deter-
mine whether one particular fusion type is associated with
poor outcomes and second, to determine whether inter-
vening genes do play a role in the biological effect of the
TMPRSS2-ERG fusion.
Few studies have addressed the issue of how the
TMPRSS2-ERG fusion is initiated in prostate carcinogene-
sis. Using a bioinformatics approach, Liu and colleagues
(2007) found Alu repeats in the TMPRSS2 and ERG break-
point regions and that the distribution of these repeats
correlates with the structure of the multiple TMPRSS2-
ERG fusion transcripts identified to date [22]. This finding
as well as the fact that genomic alterations associated with
Alu repeats have been observed to be associated with var-
ious other cancers, led Liu and colleagues (2007) to sug-
gest that these Alu elements may facilitate recombination
that leads to the fusion of the TMPRSS2 and ERG genes in
prostate cancer. To our knowledge, this is the first study to
investigate whether common genetic polymorphisms
present in the TMPRSS2 and ERG genes in germline DNA
are associated with the presence and/or type of TMPRSS2-
ERG fusion in prostate tumor tissue. No associations were
detected between the ERG SNPs and gene fusion, however
we did find an association between the TMPRSS2 SNP
rs12329760 and particular forms of the TMPRSS2-ERG
fusion. While this finding needs to be replicated, it is
interesting to speculate on how this SNP could influence
the formation of the fusion protein. The Met160Val
amino acid is highly conserved across mammals (ances-
tral form is the C allele or Val amino acid) [33] suggesting
that it may be less tolerant to substitutions. The SNP is
present in an exonic splicing enhancer (ESE) srp40 site
and the presence of the A allele is predicted to disrupt the
ESE, potentially resulting in an increased chance of exon
skipping or protein malformation [34]. It is also interest-
ing to speculate on whether other gene fusions are con-
tributing to prostate cancer development and progression.
There are a great number of proteins that have been found
to be over or under-expressed in prostate cancer and to be
associated with various stages of tumor development. It is
possible that like the fusions between TMPRSS2 and ERG,
ETV1, ETV4 and ETV5, other functionally identical
fusions are involved in changes in gene expression and
prostate cancer development but are yet to be discovered
[2,35,36].
If the association between the TMPRSS2 SNP and fusion
type is replicated and in particular, if other SNPs associ-
ated with the acquisition of this gene fusion are identified,
these data may present opportunities to augment or fur-
ther current prostate cancer diagnostic abilities. As the
gene fusion has been associated with early forms of pros-
tate cancer, a germline genetic test could be developed to
augment current screening procedures. In addition, clini-
cians are currently unable to distinguish men who will go
on to develop aggressive metastatic prostate cancer from
those whose disease will remain indolent. This may
change with recent suggestions that particular TMPRSS2-
ERG fusion types are a predictor of aggressive disease and
prostate cancer-specific mortality [4,5,7,15,19]. Again a
genetic test may be able to alert clinicians to those men
who are more at risk for aggressive disease and therefore
treatment strategies could be tailored accordingly.
There are both advantages and limitations to this study
that must be taken into consideration when interpreting
the results. Cases in this study were population-based
unlike several previous TMPRSS2-ERG studies
[4,5,18,19], there was a mean surveillance period of 11.6
years after diagnosis, and prostate cancer-specific death
was confirmed by death certificate. However, due to an
average 5-year relative survival rate for prostate cancer of
98%, there were few prostate cancer-specific deaths in this
cohort and therefore limited power. In addition, due to
the technical problems inherent to assaying TMAs using
FISH [37], only 57% of the cases could be scored. As a
consequence, while there was some evidence of an associ-
ation between multiple fusions and cancer-specific sur-
vival, there were insufficient events to observe a
statistically significant association. Lack of power is also a
concern in the SNP analyses and overall replication of the
study is a priority before any translational studies are ini-
tiated. One final concern is that only one tumor focus was
investigated per case in this study. As noted in the Intro-
duction, focal heterogeneity is typically observed so it is
possible cases were scored as normal when they did in fact
have fusion transcripts present at other foci. Key future
studies need to address the issue of whether results from
one focus are predictive of tumor behavior overall.
Conclusion
In summary, while no statistically significant associations
were observed, the data presented here show a suggestive
trend toward greater prostate cancer-specific mortality in
men whose tumors have multiple copies of TMPRSS2-
ERG. In addition, the TMPRSS2 SNP, rs12329760, was
associated with multiple copies of TMPRSS2-ERG and
fusion by translocation. These findings, if confirmed, may
provide insight into the mechanism by which the fusion
occurs and have an impact on the method of elucidating
indolent from more aggressive prostate cancers.Page 8 of 10
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